HomeProductsBuilding BlocksHeterocyclic ScaffoldsPiperidinesLasmiditan
Chemical structure of CAS 439239-90-4

Lasmiditan

CAS No.439239-90-4
MDL No.MFCD18633238
MFC19H18F3N3O2
MW377.40
InChI KeyXEDHVZKDSYZQBF-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.439239-90-4
Product NameLasmiditan

Biological Targets

HTR1F

Associated Conditions

migraine disorder·drug dependence
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine.

Therapeutic advances in neurological disorders • Vol. 8, Issue 1 • 2015
PMID: 25584073PMC: PMC4286941DOI: 10.1177/1756285614562419

Emerging treatment for chronic migraine and refractory chronic migraine.

Expert opinion on emerging drugs • Vol. 17, Issue 3 • 2012
PMID: 22862686DOI: 10.1517/14728214.2012.709846

Defining and refining 5-HT receptor targets for migraine.

The Lancet. Neurology • Vol. 11, Issue 5 • 2012
PMID: 22459548DOI: 10.1016/S1474-4422(12)70062-5

Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.

The Lancet. Neurology • Vol. 11, Issue 5 • 2012
PMID: 22459549DOI: 10.1016/S1474-4422(12)70047-9

Documentation